A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9.

Choudry, G A; Stewart, P A; Double, J A; Krul, M R; Naylor, B; Flannigan, G M; Shah, T K; Brown, J E; Phillips, R M

Choudry, G A; Stewart, P A; Double, J A; Krul, M R; Naylor, B; Flannigan, G M; Shah, T K; Brown, J E; Phillips, R M.

Affiliation

Choudry GA; Cancer Research Unit, University of Bradford, Bradford, BD7 1DP, UK.

Br J Cancer ; 85(8): 1137-46, 2001 Oct 19.

Article in En | MEDLINE | ID: mdl-11710826

Subject(s)

Antineoplastic Agents/therapeutic use; Aziridines/therapeutic use; Indolequinones; Indoles/therapeutic use; Quinone Reductases/metabolism; Urinary Bladder Neoplasms/drug therapy; Aziridines/pharmacokinetics; Humans; Hydrogen-Ion Concentration; Immunohistochemistry; Indoles/pharmacokinetics; Substrate Specificity; Urinary Bladder/enzymology; Urinary Bladder Neoplasms/enzymology

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quinone Reductases / Aziridines / Urinary Bladder Neoplasms / Indolequinones / Indoles / Antineoplastic Agents Limits: Humans Language: En Journal: Br J Cancer Year: 2001 Document type: Article Affiliation country: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google